— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected.
— Revenues grew 137% to $48.8 million, vs. $47.6 million expected.
— Global revenue for Galafold was $48.8 million.
— FY19 Galafold revenue is expected to be $170 million to $180 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Tyson Foods (TSN) Q2 2024 Earnings: Key financials and quarterly highlights
Tyson Foods, Inc. (NYSE: TSN) reported second quarter 2024 earnings results today. Sales dipped slightly to $13.07 billion from $13.1 billion in the same period a year ago. Net income
After mixed Q2, what awaits Apple (AAPL) in the second half?
Apple’s (NASDAQ: AAPL) stock rallied this week after the gadget giant reported stronger-than-expected Q2 results and announced the largest-ever share buyback program. The company is investing heavily in the business,
What to expect when Tyson Foods (TSN) reports Q2 2024 earnings results
Shares of Tyson Foods, Inc. (NYSE: TSN) stayed green on Friday. The stock has gained 8% over the past three months. The branded foods company is slated to report its
